Revive Therapeutics Provides Update on Research Study Evaluating Bucillamine for Nerve Agent Exposure

by rvvadmin | May 12, 2025 | 2025

TORONTO, May 12, 2025 – Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for infectious diseases and medical countermeasures,...

Revive Therapeutics Announces Proposed Shares for Debt Transaction

by rvvadmin | Apr 21, 2025 | 2025

TORONTO, April 21, 2025 – Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for infectious diseases, rare disorders, and...

Revive Therapeutics to Investigate Bucillamine’s Potential in Cancer Treatment

by rvvadmin | Apr 10, 2025 | 2025

TORONTO, April 10, 2025 – Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for infectious diseases, rare disorders, and...

Revive Therapeutics Announces Acquisition of Molecular Hydrogen Program

by rvvadmin | Apr 1, 2025 | 2025

TORONTO, April 01, 2025 – Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for infectious diseases, rare disorders, and...

Revive Therapeutics Announces Results of Annual Shareholder Meeting

by rvvadmin | Mar 19, 2025 | 2025

TORONTO, March 19, 2025 –  Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for infectious diseases, rare disorders, and...